Liver transcriptomic changes associated with ritonavir-induced hyperlipidemia in sensitive and resistant strains of rats

Veterinary Journal

Volumn 185, Issue 1, 2010, Pages 75-82

  Yang, Yi ^a   Dahly Vernon, Annette J ^b   Blomme, Eric A G ^a   Lai Zhang, Jie ^a   Kempf, Dale J ^a   Marsh, Kennan C ^a   Harrington, Yvette A ^b   Nye, Steven H ^b   Evans, Darin L ^b   Roman, Richard J ^b,c   Jacob, Howard J ^b,c   Waring, Jeffrey F ^a  

^a ABBOTT LABORATORIES   (United States)

^b PhysioGenix Inc   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Biomarkers; Gene expression; Lipids; Liver; Rat; Ritonavir

Indexed keywords

BILE ACID; BIOLOGICAL MARKER; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; RITONAVIR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID SYNTHESIS; BROWN NORWAY RAT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUCONEOGENESIS; HYPERLIPIDEMIA; LEWIS RAT; LIVER METABOLISM; MALE; MICROARRAY ANALYSIS; NONHUMAN; RAT; RAT STRAIN; STRAIN DIFFERENCE; TRANSCRIPTOMICS; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HIV PROTEASE INHIBITORS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIVER; MALE; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RITONAVIR;

HUMAN IMMUNODEFICIENCY VIRUS; RATTUS;

EID: 77953664067     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2010.04.017     Document Type: Article

References (29)

1. Bandsma R.H., Smit G.P., Kuipers F. Disturbed lipid metabolism in glycogen storage disease type 1. European Journal of Pediatrics 2002, 161:65-69.
2. Blomme E.A., Yang Y., Waring J.F. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicology Letters 2009, 186:22-31.
3. Caldwell G.W., Ritchie D.M., Masucci J.A., Hageman W., Yan Z. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Current Topics in Medicinal Chemistry 2001, 1:353-366.
4. Desmet V.J. Histopathology of cholestasis. Verhandlungen der Deutschen Gesellschaft für Pathology 1995, 79:233-240.
5. Dube M.P., Stein J.H., Aberg J.A., Fichtenbaum C.J., Gerber J.G., Tashima K.T., Henry W.K., Currier J.S., Sprecher D., Glesby M.J. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical Infectious Disease 2003, 37:613-627.
6. Elisaf M. Effects of fibrates on serum metabolic parameters. Current Medical Research and Opinion 2002, 18:269-276.
7. Fourie C.M., Van Rooyen J.M., Kruger A., Schutte A.E. Lipid abnormalities in a never-treated HIV-1 subtype C-infected African population. Lipids 2010, 45:73-80.
8. Fukuda H., Katsurada A., Iritani N. Nutritional and hormonal regulation of mRNA levels of lipogenic enzymes in primary cultures of rat hepatocytes. Journal of Biochemistry (Tokyo) 1992, 111:25-30.
9. Goetzman E.S., Tian L., Nagy T.R., Gower B.A., Schoeb T.R., Elgavish A., Acosta E.P., Saag M.S., Wood P.A. HIV protease inhibitor ritonavir induces lipoatrophy in male mice. AIDS Research and Human Retroviruses 2003, 19:1141-1150.
10. Hui D.Y. Effects of HIV protease inhibitor therapy on lipid metabolism. Progress in Lipid Research 2003, 42:81-92.
11. Kacew S. Confounding factors in toxicity testing. Toxicology 2001, 160:87-96.
12. Kinowaki M., Tanaka S., Maeda Y., Higashi S., Okuda K., Setoguchi T. Half-life of cholesterol 7alpha-hydroxylase activity and enzyme mass differ in animals and humans when determined by a monoclonal antibody against human cholesterol 7alpha-hydroxylase. Journal of Steroid Biochemistry and Molecular Biology 2002, 81:377-380.
13. Korkalainen M., Tuomisto J., Pohjanvirta R. Primary structure and inducibility by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) of aryl hydrocarbon receptor repressor in a TCDD-sensitive and a TCDD-resistant rat strain. Biochemical and Biophysical Research Communications 2004, 315:123-131.
14. Lee G.A., Rao M.N., Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Current HIV/AIDS Reports 2005, 2:39-50.
15. Lenhard J.M., Croom D.K., Weiel J.E., Winegar D.A. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20:2625-2629.
16. Lum P.Y., He Y.D., Slatter J.G., Waring J.F., Zelinsky N., Cavet G., Dai X., Fong O., Gum R., Jin L., Adamson G.E., Roberts C.J., Olsen D.B., Hazuda D.J., Ulrich R.G. Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia. Genomics 2007, 90:464-473.
17. Molla A., Granneman G.R., Sun E., Kempf D.J. Recent developments in HIV protease inhibitor therapy. Antiviral Research 1998, 39:1-23.
18. Moyle G. Metabolic issues associated with protease inhibitors. Journal of Acquired Immune Deficiency Syndromes 2007, 45:19-26.
19. Munteanu A., Ricciarelli R., Zingg J.M. HIV protease inhibitors-induced atherosclerosis: prevention by alpha-tocopherol. IUBMB Life 2004, 56:629-631.
20. Norlin M., Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Current Molecular Medicine 2007, 7:199-218.
21. Pandak W.M., Schwarz C., Hylemon P.B., Mallonee D., Valerie K., Heuman D.M., Fisher R.A., Redford K., Vlahcevic Z.R. Effects of CYP7A1 overexpression on cholesterol and bile acid homeostasis. American Journal of Physiology Gastrointestinal and Liver Physiology 2001, 281:878-889.
22. Periard D., Telenti A., Sudre P., Cheseaux J.J., Halfon P., Reymond M.J., Marcovina S.M., Glauser M.P., Nicod P., Darioli R., Mooser V. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999, 100:700-705.
23. Pullinger C.R., Eng C., Salen G., Shefer S., Batta A.K., Erickson S.K., Verhagen A., Rivera C.R., Mulvihill S.J., Malloy M.J., Kane J.P. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. Journal of Clinical Investigation 2002, 110:109-117.
24. Reasor M.J., McCloud C.M., Beard T.L., Ebert D.C., Kacew S., Gardner M.F., Aldern K.A., Hostetler K.Y. Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats. Toxicology 1996, 106:139-147.
25. Riddle T.M., Kuhel D.G., Woollett L.A., Fichtenbaum C.J., Hui D.Y. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. Journal of Biological Chemistry 2001, 276:37514-37519.
26. Sherer R. HIV, HAART, and hyperlipidemia: balancing the effects. Journal of Acquired Immune Deficiency Syndromes 2003, 34:123-129.
27. Society of Toxicology Guiding principles in the use of animals in toxicology. Adopted by the Society of Toxicology in July 1989. Toxicology and Applied Pharmacology 2002, 178:4.
28. Tien E.S., Davis J.W., Vanden Heuvel J.P. Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor alpha coregulator. Journal of Biological Chemistry 2004, 279:24053-24063.
29. Yeh R.F., Gaver V.E., Patterson K.B., Rezk N.L., Baxter-Meheux F., Blake M.J., Eron J.J., Klein C.E., Rublein J.C., Kashuba A.D. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. Journal of Acquired Immune Deficiency Syndromes 2006, 42:52-60.